Publications by authors named "Pieway Hwang"
Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.
J Child Adolesc Psychopharmacol
May 2005
Objectives: The aim of this study was to assess whether once-daily Concerta extended-release (XR) methylphenidate (MPH) is associated with: (1) better compliance; (2) decreased likelihood of accidents/injuries; and (3) lower health-care resource use over a 1-year period than 3-times-daily immediate-release (IR) MPH in children with attention deficit hyperactivity disorder (ADHD).
Methods: Multivariate regression analyses were performed using an administrative database. Inclusion criteria were: (1) an age of 6-12 years at the date of first prescription for XR/IR MPH (index date); (2) patient-level data available for least 6 months before and 12 months after the index date; (3) no ADHD medications in the 6-month prior period; and (4) no XR MPH use by the IR MPH group.
Article Synopsis
- The study examines the weight gain effects of novel atypical antipsychotics (NAPs) in patients with schizophrenia and related disorders using data from the Canadian National Outcomes Measurement Study in Schizophrenia (CNOMSS).
- Quetiapine (QUE) was found to be associated with the highest mean weight gain, with over half of the patients gaining more than 7% of their baseline weight, compared to lower percentages for olanzapine (OLZ) and risperidone (RIS).
- The results suggest that patients on QUE have significantly higher odds of experiencing substantial weight gain compared to those on RIS, highlighting important considerations for clinicians when prescribing these medications.